HHS grants $100M to healthcare systems

HHS’ Office of the Assistant Secretary for Preparedness and Response has granted $100 million to help healthcare systems prepare for a surge of COVID- patients.

The funds, authorized in the Coronavirus Preparedness and Response Supplemental Appropriations Act, will directly support the National Special Pathogen System, which will leverage regional, tiered infrastructure already in place from the U.S. Ebola response. The funds will be dispersed to hospitals for special pathogen preparedness directly from hospital associations, which will also collaborate across healthcare systems and coalitions.

The system includes the National Emerging Special Pathogens Training and Education Center (NETEC), 10 regional Ebola and other special pathogen treatment centers, 62 HHS Hospital Preparedness Program agreement recipients and their state of jurisdiction treatment centers and hospital associations.

“We cannot beat the COVID-19 pandemic without getting America’s healthcare workers the training and resources they need to respond to this novel threat, and these funds secured from Congress by President Trump will help make that happen," HHS Secretary Alex Azar said in a statement. "America’s healthcare providers are doing an incredible job, and this funding is one more way that the Trump Administration is supporting their heroic efforts. With help from HHS, for years, America’s healthcare providers have been developing sophisticated, coordinated ways to respond to new threats, and we are working with them to draw on those investments today.”

NETEC is made up of three healthcare facilities that care for Ebola patients, including Emory University, University of Nebraska Medical Center/Nebraska Medicine, and New York Health and Hospitals Corporation/Bellevue Hospital Center. NETEC helps other healthcare facilities prepare to care for patients with highly infectious diseases and provides other assistance and education.

The 10 Ebola healthcare facilities can specially treat and receive special pathogen patients, with enhanced capability and capacity for highly infectious diseases.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup